				Complete if Known		
1		•		Application Number	10/804,331	
INFORM	JATION DI	SCLOSUR	₹E	Filing Date	March 19, 2004	
STATEMENT BY APPLICANT				First Named Inventor	Smith et al.	
SIAIL	11L141 D1 1	AI I LIOAN	• •	Group Art Unit	1648	
luse as m	(use as many sheets as necessary)			Examiner Name	B. Blumel	
Sheet	E1	of	E1	Attorney Docket Number	9368-5	

Examiner	Cite No.	No. U.S. Patent Document		Name of Patentee or Applicant of Cited	Date of Publication of Cited	
Initials*			Kind Code (if known)	Document	Document MM-DD-YYYY	
/BB/	1.	US 2004/0055037		Yuri Gleba	3/18/2004	
<u> </u>	2.	US 2004/0255347		Victor Klimyuk	12/16/2004	
	3.	US 2004/0088764		Yuri Gleba	5/6/2004	
	4.	US 2005/0014150		Joseph Atabekov	1/20/2005	
	5.	US 2005/0059004		Joseph Atabekov	3/17/2005	
	6.	US 2005/0123555		Olmsted et al.	6/9/2005	
/BB/	7.	US 2006/0177819		Smith et al.	8/10/2006	
		US				
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		US				
		US				

				FOREIGN PA	TENT DOCUMENTS		
	Cite	Foreign Patent Document			Name of Patentee or Applicant of Cited	Date of Publication of	Translation
	No.	Office	Number	Kind Code (if known)	Document	Cited Document MM-DD-YYYY	

OTHER NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.). date. page(s), volume-issue number(s), publisher, city and/or country where published	T					
			·					

			r
Examiner Signature		Date Considered	
L. Adminici Olymaidie	/D : DI .//	5010 00110100	00/44/2007
	Benjamin Blumel/	1	09/11/2007
			007 1 17 200 1

Substitute	form 1449A/PTO		OIPE	C	omplete if Known
Cabbinate	.0		4	Application Number	10/804,331
INFORM	ATION DISCL	OSURÉ	May a see	Filing Date	March 19, 2004
STATEM	ENT BY APP	ICANT	NOV O 8 2005	First Named Inventor	Jonathan Smith
SIAIEM	ENI DI AFFI	FICKIA (S. M.	Group Art Unit	1648
luse as ma	ny sheets as nec	essarv)		Examiner Name	TBA
Sheet	1	of	PHOEMARK	Attorney Docket Number	9368-5

	U.S. PATENTS AND PATENT PUBLICATIONS								
Examiner	Cite No.	U.S. Patent D		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document				
Initials*		Number	Kind Code (if known)	Document	MM-DD-YYYY				
/BB/	1.	US-5,827,658	 	Liang et al.	10/27/1998				
7507	2	US-2004/0029279		Kovacs et al.	02/12/2004				
	3	US-2005/0118251		Nagata et al.	06/02/2005				
	 <u>4</u>	US-2003/0148262	 	Polo et al.	08/07/2003				
/BB/	5.	US-2003/0232324		Polo et al.	12/18/2003				

				FOREIGN PAT	ENT DOCUMENTS		
	Cite		Foreign Patent Docu	ment	Name of Patentee or Applicant of Cited Document	Date of Publication of	Translation
	No.	Office	Number	Kind Code (if known)		Cited Document MM-DD-YYYY	
/BB/	6.	wo	99/51263		MacDonald et al.	10/14/1999	

		OTHER NON PATENT LITERATURE DOCUMENTS	·
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Т
/BB/	7.	Davis et al. "Alphavirus Replicon Particles as Candidate HIV Vaccines" IUBMB Life 53: 209-211 (2002)	
	8.	Baric et al. "Expression and Self-Assembly of Norwalk Virus Capsid Protein from Venezuelan Equine Encephalitis Virus Replicons" <i>Journal of Virology</i> 76(6): 3023-3030 (2002)	
	9.	Eiben et al. "Establishment of an HLA-A*0201 Human Papillomavirus Type 16 Tumor Model to Determine the Efficacy of Vaccination Strategies in HLA-A*0201 Transgenic Mice" Cancer Research 62: 5792-5799 (2002)	
	10.	Eralp et al. "Doxorubicin and Paclitaxel Enhance the Antitumor Efficacy of Vaccines Directed Against HER 2/neu in a Murine Mammary Carcinoma Model" <i>Breast Cancer Research</i> 6:R275-R283 (2004)	
	11.	Lee et al. "Candidate Vaccine Against Botulinum Neurotoxin Serotype A Derived from a Venezuelan Equipe Encenhalitis Virus Vector System" Infection and Immunity 69(9): 5709-5715 (2001)	
	12.	Lee et al. "Immune Protection Against Staphylococcal Enterotoxin-Induced Toxic Shock by Vaccination with a Venezuelan Equine Encephalitis Virus Replicon" <i>Journal of Infectious Diseases</i> 185: 1192-1196 (2002)	
	13.	MacDonald et al. "Role of Dendritic Cell Targeting in Venezuelan Equine Encephalitis Virus Pathogenesis" Journal of Virology 74(2): 914-922 (2000)	
	14.	Nelson et al. "Venezuelan Equine Encephalitis Replicon Immunization Overcomes Intrinsic Tolerance and Elicits Effective Anti-Tumor Immunity to the "self" Tumor-Associated Antigen, neu in a Rat Mammary Tumor Model" Breast Cancer Research and Treatment 63R: 1-15 (2003)	
	15.	Pushko et al. "Individual and Bivalent Vaccines Based on Alphavirus Replicons Protect Guinea Pigs Against Infection with Lassa and Ebola Viruses" <i>Journal of Virology</i> 75(23): 11677-11685 (2001)	
	16.	Schultz-Cherry et al. "Influenza Virus (A/HK/156/97) Hemagglutinin Expressed by an Alphavirus Replicon System Protects Chickens Against Lethal Infection with Hong Kong-Origin H5N1 Viruses" Vimical 278: 55-59 (2000)	
	17.	Wang et al. "Alphavirus Replicon Particles Containing the Gene for HER2/neu Inhibit Breast Cancer Growth and Tumorigenesis" Breast Cancer Research 7; R145-R155 (2005)	
	18.	Velders et al. "Eradication of Established Tumors by Vaccination with Venezuelan Equine Encephalitis Virus Replicon Particles Delivering Human Papillomavirus 16 E7 RNA" Cancer Research 61: 7861-7867 (2001)	
/BB/	19.	Wilson et al. "Protection from Ebola Virus Mediated by Cytotoxic T Lymphocytes Specific for the Viral Nucleoprotein" <i>Journal of Virology</i> 75(6): 2660-2664 (2001)	

Examiner Signature /Benjamin Blumel/	Date Considered	07/16/2007
--------------------------------------	-----------------	------------

<u> </u>			0.00	Complete if Known	
			(4	Application Number	10/804,331
INFORM	MATION DIS	CLOSURE	3	Filing Date	March 19, 2004
	MENT BY A		MANUA. 🖦	First Named Inventor	Smith et al.
JULIA I			13	Group Art Unit	1648
(use as m	nany sheets as	necessary)	Ay.	Examiner Name	
Sheet	E1	of	Et larene	Attomey Docket Number	9368-5

	U.S. PATENTS AND PATENT PUBLICATIONS								
Examiner Initials*	Cite No.	ite No. U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document				
		Number	Kind Code (if known)	Document	MM-DD-YYYY				
/BB/	1.	US- 7,045,335		Smith et al.	05-16-2006				
		US-							
	1	US-							
	1	US-							
		US-							
		US-							

				FOREIGN P	ATENT DOCUMENTS		
Examiner Initials*	Cite				Name of Patentee or Applicant of Cited	Date of	Translation
	No.	Office	Number	Kind Code (if known)	Document	Publication of Cited Document MM-DD-YYYY	
/BB/	2.	WO	02/10578	A1	Visteon Global Technologies, Inc.	02-07-2002	
	 						

Examiner Initials* Cite No. /BB/ 3.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published						
		Gidwitz et al. "Differences in virion stability among Sindbis virus pathogenesis mutants" Virus Research 10:225-240 (1988).						
	4.	Johnston et al. "Studies of Alphavirus Virulence Using Full-Length Clones of Sindbis and Venezuelan Equine Encephalitis Viruses" M.A. Brinton et al. (eds), New Aspects of Positive Strand RNA Viruses, pp. 334-339, ASM Press (1990).						
	5.	Kaufman et al. "Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus" Nucleic Acids Research 19(16):4485-4490 (1991).						
	6.	Khromykh. "Replicon-based vectors of positive strand RNA viruses" Current Opinion in Molecular Therapeutics 2(5):555-569 (2000).						
	7.	Lemm et al. "Assembly of Functional Sindbis Virus RNA Replication Complexes: Requirement for Coexpression of P123 and P34" Journal of Virology 67(4):1905-1915 (1993).						
	8.	Olmsted et al. "Sindbis Virus Mutants Selected for Rapid Growth in Cell Culture Display Attenuated Virulence in Animals" Science 225(4660):424-427 (1984).						
	9.	Polo et al. "A Model for In Vitro Development of Live, Recombinant Alphavirus Vaccines" <u>Vaccines 90:</u> <u>Modern Approaches to New Vaccines Including Prevention of AIDS</u> , pp. 105-108, Brown et al. (eds), Cold Spring Harbor Laboratory, 1990.						
	10.	Polo et al. "Mutational Analysis of Virulence Locus in the E2 Glycoprotein Gene of Sindbis Virus" Journal of Virology 65(11):6358-6361 (1991).						
	11.	Tugizov et al. "Mutated Forms of Human Cytomegalovirus Glycoprotein B Are Impaired in Inducing Syncytium Formation" Virology 209:580-591 (1995).						
/BB/	12.	Vaz-Santiago "Ex Vivo Stimulation and Expansion of both CD4+ and CD8+ T Cells from Peripheral Blood Mononuclear Cells of Human Cytomegalovirus-Seropositive Blood Donors by Using a Soluble Recombinant Chimeric Protein, IE1-pp65" Journal of Virology 75(17):7840-7847 (2001).						

Examiner Signature	/Benjamin Blumel/	Date Considered	07/16/2007	



NO 24 2004 333

	Pate OF DO	nt and Tr	Artment of Commademark Office ITS CITED BY AF	PPLICANT		Attorney Do	cket Number 9368.5	r	Serial No. 10/804,331
						Applicants:	Smith et al.		
						Filing Date:	March 19, 2	2004	Group 1648
				U. S. PATENT DO	CUME	NTS			
Examiner Initial			ument mber	Date		Name	Class	Subclass	Filing Date if Appropriate
/BB/	1.	US 20	003/0119182	June 26, 2003	Rayı	ner et al.			
	· · · · · · · · · · · · · · · · · · ·	<u> I AI</u>	,	FOREIGN PATEN	r DOC	UMENTS		<u> </u>	
		Docus	ment Number	Date	. 500	Country	Class	Subclass	
/BB/	2.	woo	03/023026 A	March 20, 20	03				
			OTHER DOCU	MENTS (Including	Author	, Title, Date, Per	tinent Pages	, Etc.)	
/BB/		3.	· · · · · · · · · · · · · · · · · · ·	rch Report correspo					r 25, 2004
		4.	Exogenous Prote	n from Bovine Chro ins using a Recombi er" <i>Molecular and C</i>	inant Se	emliki Forest Vir	us Containii		
		5.	Semliki Forest V	sient Gene Expression T7 Tirus Expressing T7 3(1):51-56 (1999)					combinant
		6.	Pugachev et al. " Picornavirus Inte	Development of a R ernal Ribosome Entr 10811-10815 (2000	y Site I				
		7.		phavirus Vectors an		ination" Reviews	in Medical	Virology 12(5):279-296
		8.	Shi Pei-Yong et	al. "Construction and w York Strain of We				-233	
		9.	Wang et al. "Cor Cap-Independen	re Protein-Coding Se t Translation Directe ogy 74(23):11347-11	d by th	e Internal Ribose			
		10.	Wen Xiao-Yan e	t al. "Tricistronic Vi the Immunotherapy	ral Ved	tors Co-Express			
/BB/		11.	Wilson et al. "Na	aturally Occurring D ne Entry Sites" Mole					

EXAMINER /Benjamin Blumel/ DATE CONSIDERED 07/16/2007

ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18

Stylesheet Version v18.0

Title of Invention

Improved Alphavirus Replicons and Helper Constructs

Application Number:

10/804331

Confirmation Number:

7017

First Named Applicant:

Jonathan Smith

Attorney Docket Number:

9368.5

Art Unit:

1648

Examiner:

Search string:

(4650764 or 5091309 or 5185440 or 5217879 or 5505947 or 5639650 or 5643576 or 5739026 or 5766602 or 5789245 or 5792462 or 5811407 or 5814482 or 5843723 or 6008035 or 6015686 or 6015694 or 6146874 or 6156558 or 6190666 or 6224879 or 6242259 or 6261570 or 6329201 or 6342372 or 6376236 or 6391632 or 6426196

).pn

US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents Data

init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
/BB/	1	4650764	1987-03-17	Temin			
	2	5091309	1992-02-25	Schlesinger			
	3	5185440	1993-02-09	Davis			
Ħ	4	5217879	1993-06-08	Huang			
	5	5505947	1996-04-09	Johnston			
	6	5639650	1997-06-17	Johnston			
	7	5643576	1997-07-01	Johnston			
	8.	5739026	1998-04-14	Garoff			
\Box	9	5766602	1998-06-16	Xiong			
	10	5789245	1989-08-04	Dubensky			,
	11	5792462	1998-08-11	Johnston			
	12	5811407	1998-09-22	Johnston			
	13	5814482	1998-09-29	Dubensky			
	14	5843723	1998-12-01	Dubensky			
\Box	15	6008035	1999-12-28	Johnston			
\Box	16	6015686	2000-01-18	Dubensky			
	17	6015694	2000-01-18	Dubensky			
	18	6146874	2000-11-14	Zolutukhin			
	19	6156558	2000-12-05	Johnston			
/BB	/ 20	6190666	2001-02-20	Garoff			



10/804,331

			4.50			
	/B B /	21	6224879	2002-05-01	Sjoberg	
ı		22	6242259	2001-06-05	Polo	
Ī		23	6261570	2001-07-17	Parker	
Ī		24	6329201	2002-12-11	Polo	
1		25	6342372	2002-01-29	Dubensky	
ı		26	6376236	2002-04-23	Dubensky	
ľ		27	6391632	2002-05-21	Dubensky	
Ī	/B B /	28	6426196	2002-07-30	Dubensky	


Signature

Examiner Name	Date
/Renjamin Blumel/	07/16/2007

Substitute form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT.

(use as many sheets as necessary)
Sheet C1 of



				AND PATENT PUBLICATIONS		
Examiner	Cite	U.S. Patent Doo	cument	Name of Patentee or Applicant of Cited	Date of Publication of Cited	
Initials*	No.	Number	Kind Code (if known)	— Document	Document MM-DD-YYYY	
/BB/	1.	US-2001/0016199		Johnston et al.	08/23/2001	
	2.	US-2002/0018766		Roberts et al.	02/14/2002	
	3.	US-2002/0034521		Lee et al.	03/21/2002	
l	4.	US-2002/0102273		Grieve et al.	08/01/2002	
	5.	US-2002/0141975		Olmsted et al.	08/31/2004	
	6.	US-2002/0164582		Hart et al.	11/07/2002	
	7.	US-2003/0021766		Vadjy et al.	01/30/2003	
	8.	US-2003/0091591	·	Xiong et al.	05/15/2003	
	9.	US-2003/0096397		Schlesinger et al.	05/22/2003	
	10.	US-2003/0120060		Gonczol et al.	06/26/2003	
	11.	US-2003/0152590		Hevey et al.	08/14/2003	
	12.	US-2003/0232036		Johnston et al.	12/18/2003	
	13.	US-2004/0008458		Kase et al.	01/15/2004	
	14.	US-2004/0009183		Lee et al.	01/15/2004	
	15.	US-2004/0009945		Lee et al.	01/15/2004	
	16.	US-2004/0030117		Johnston et al.	02/12/2004	
	17.	US-2004/0121466		Johnston et al.	06/24/2004	
	18.	US-2004/0146859		Hart et al.	07/29/2004	
	19.	US-2004/0166573		Smith et al.	08/26/2004	
	20.	US-2004/0208848		Smith et al.	10/21/2004	
	21.	US-2005/0031592		Doolan et al.	02/10/2005	
	22.	US-2005/0054107	•	Chulay et al.	03/10/2005	
	23.	US-4,708,871	7	Geysen	11/24/1987	
	24.	US-5,521,082		Lewis et al.	05/28/1996	
	25.	US-5,703,057		Johnston et al.	12/30/1997	
	26.	US-5,726,022		Burmer	03/10/1998	
	27.	US-5,831,016		Wang et al.	3/11/1998	
	28.	US-5,843,723		Dubensky et al.	12/01/1998	
	29.	US-5,853,719		Nair et al.	12/29/1998	
	30.	US-5,958,738		Lindermann et al.	09/28/1999	
	31.	US-5,989,553		Johnston et al.	11/23/1999	
	32.	US-6,194,191		Zhang et al.	02/27/2001	
	33.	US-6,197,502		Renner et al.	03/06/2001	
	34.	US-6,267,967		Johnston et al.	07/31/2001	
	35.	US-6,306,388		Nair et al.	10/23/2001	
	36.	US-6,485,958		Blanch et al.	11/26/2002	
	37.	US-6,495,143		Lee et al.	12/01/2001	
	38.	US-6,521,235		Johnston et al.	02/18/2003	
	39.	US-6,531,135		Johnston et al	03/11/2003	
	40.	US-6,541,010		Johnston et al.	04/01/2003	
	41.	US-6,583,121		Johnston et al.	06/24/2003	
	42.	US-6,767,699		Polo et al.	07/27/2004	
	43.	US-6,770,283		Garoff et al.	08/03/2003	
	44.	US-6,783,939		Olmsted et al.	08/31/2004	
L_/BB/	45.	US-6,844,188		MacDonald et al.	01/18/2005	

Examiner Signature	/Benjamin Blumel/	Date Considered	07/16/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute form 1449A/PTO				Complete if Known			
INFORMATION DISCLOSURE				Application Number	10/804,331		
				Filing Date	March 19, 2004	-	
	STATEMENT BY APPLICANT		First Named Inventor	Smith			
SIAIL		AT LIOMI	•	Group Art Unit	1648		
luse as r	(use as many sheets as necessary)		Examiner Name	Unknown			
Sheet	C2	of	C4	Attorney Docket Number	9368.5		

				FOREIGN PA	TENT DOCUMENTS		
Examiner	Cite		Foreign Patent Docum	ent	Name of Patentee or Applicant of Cited Document	Date of Publication of	Translation
Initials*	No.	Office	Number	Kind Code (if known)		Cited Document MM-DD-YYYY	
/BB/	46.		WO 99/07834	,		02/18/1999	
1	47.		WO 99/08706			02/25/1999	
	48.		WO 01/16343 A1			03/08/2001	
	49.		WO 00/39302			07/06/2000	
	50.		WO 02/03917			01/17/2002	
	51.		WO 02/04493			01/17/2002	
	52.	i	WO 03/083065 A2			10/09/2003	
	53.		WO 04/055166			07/01/2004	
	54.		WO 04/055167			07/01/2004	
	55.	<u> </u>	WO 04/085660			10/07/2004	
/BB/	56.	<u> </u>	WO 05/007689			01/27/2005	

		OTHER NON PATENT LITERATURE DOCUMENTS	
Examine r Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Т
/BB/	57.	Balasuriya et al. "Alphavirus Replicon Particles Expressing the Two Major Envelope Proteins of Equine Arteritis Virus Induce High Level Protection Against Challenge with Virulent Virus in Vaccinated Horses" Vaccine 20:1609-1617 (2002)	
	58.	Barry et al. "Expression Library Immunization to Discover and Improve Vaccine Antigens" Immunological Reviews 199:68-83 (2004)	
	59.	Bell et al. "Effect of Low NaCl Medium on the Envelope Glycoproteins of Sindbis Virus" Journal of Virology 25(3):764-769 (1978)	
	60.	Bergman et al. "Long-Term Survival of Dogs with Advanced Malignant Melanoma after DNA Vaccination with Xenogeneic Human Tyrosinase: A Phase I Trial" Clin. Cancer Research 9:1284-1290 (2003)	
	61.	Bernard et al. "Mutations in the E2 Glycoprotein of Venezuelan Equine Encephalitis Virus Confer Heparan Sulfate Interaction, Low Morbidity, and Rapid Clearance from Blood of Mice" Virology 276:93-103 (2000)	
	62.	Bourne et al. "Preconception Immunization with a Cytomegalovirus (CMV) Glycoprotein Vaccine Improves Pregnancy Outcome in a Guinea Pig Model of Congenital CMV Infection" The Journal of Infectious Diseases 183:59-64 (2001)	
	63.	Carlson et al. "Expression, Purification and Characterization of a Soluble Form of Human Cytomegalovirus Glycoprotein B" Virology 239:198-205 (1997)	
	64.	Casimiro et al. "Vaccine-Induced Immune Responses in Rodents and Nonhuman Primates by Use of a Humanized Immunodeficiency Virus Type 1 pol Gene" Journal of Virology 76:185-195 (2002)	
	65.	Chatterjee et al. "Modification of Maternal and Congenital Cytomegalovirus Infection by Anti- Glycoprotein B Antibody Transfer in Guinea Pigs" The Journal of Infectious Diseases 183:1547-1553 (2001)	
	66.	Davis et al. "A Single Nucleotide Change in the E2 Glycoprotein Gene of Sindbis Virus Affects Penetration Rate in Cell Culture and Virulence in Neonatal Mice" Proc. Natl. Acad. Sci. USA 83:6771-6775 (1986)	
	67.	Davis et al. 1989. In Vitro Synthesis of Infectious Venezuelan Equine Encephalitis Virus RNA from a cDNA Clone: Analysis of A Viable Deletion Mutant. Virology 171:189-204	
	68.	Geisbert et al. "Evaluation in Nonhuman Primates of Vaccines Against Ebola Virus" Emerging Infect. Dis. 8(5):503-507 (2002)	
/BB/	69.	Geysen et al. "A Priori Delineation of a Peptide which Mimics a Discontinuous Antigenic Determinant" Molecular Immunology 23(7):709-715 (1986)	

			· · · · · · · · · · · · · · · · · · ·
Examiner Signature		Date Considered	
- Examinor Orginaturo	/Benjamin Blumel/		
1	/Donjaniin Diamor		L 07/16/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute form 1449A/PTO				Complete if Known		
				Application Number	10/804,331	
INFORM	MATION DIS	CLOSUR	:	Filing Date	March 19, 2004	
STATEMENT BY APPLICANT		First Named Inventor	Smith			
JIAIL	MENT DIA			Group Art Unit	1648	
(use as m	nany sheets as	necessary)		Examiner Name	Unknown	
Sheet	C3	of	C4	Attorney Docket Number	9368.5	•

/BB/	70.	Geysen et al. "Use of Peptide Synthesis to Probe Viral Antigens for Epitopes to a Resolution of a Single Amino Acid" Proceedings of the National Academy of Sciences of the United States of America	
	71.	81(13):3998-4002(1984) Golzio et al. "Cell Synchronization Effect on Mammalian Cell Permeabilization and Gene Delivery by Electronic Field" Biochim. Biophys. Acta 1563:23-28 (2002)	
	72.	Gonczol and Plotkin "Development of a Cytomegalovirus Vaccine: Lessons from Recent Clinical Trials" Exp. Opin. Biol. Ther. 1(3):401-412 (2001)	
	73.	Gyulai et al. "Cytotoxic T Lymphocyte (CTL) Responses to Human Cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in Healthy Individuals: Reevaluation of Prevalence of IE1-Specific CTLs" J. Infect. Dis. 181:1537-1546(2000)	
	74.	Hahn et al. "Infectious Sindbis Virus Transient Expression Vectors for Studying Antigen Processing and Presentation" Proc. Natl. Acad. Sci. USA 89:2679-2683 (1992)	
	75.	Hariharan et al. "DNA Immunization Against Herpes Simplex Virus: Enhanced Efficacy Using a Sindbis Virus-Based Vector" Journal of Virology 72(2):950-958 (1998)	
	76.	Heiser et al. "Autologous Dendritic Cells Transfected with Prostate-Specific Antigen RNA Stimulate CTL Responses Against Metastatic Prostate Tumors" J. Clinical Inv. 109(3):409-417 (2002)	
	77.	Hevey et al. "Marburg Virus Vaccines Based upon Alphavirus Replicons Protect Guinea Pigs and Nonhuman Primates" Virology 251:28-37 (1998)	
	78.	Hill et al. "RNA-RNA Recombination in Sindbis Virus: Roles of the 3' Conserved Motif, Poly (A) Tail, and Nonviral Sequences of Template RNAs in Polymerase Recognition and Template Switching" Journal of Virology 71:2693-2704 (1997)	
	79.	International Search Report issued for PCT/2004/021772; mailed on December 28, 2004	
	80.	International Search Report issued for PCT/US03/39723; mailed on August 17, 2004	
	81.	International Search Report issued for PCT/US03/39725; mailed on December 3, 2004	
	82.	Koller et al. "A High-Throughput Alphavirus-Based Expression Cloning System for Mammalian Cells" Nature Biotech. 19:851-855 (2001)	
	83.	Kumamoto et al. "Induction of Tumor-Specific Protective Immunity by in situ Langerhans Cell Vaccine" Nature Biotech. 20:64-69 (2002)	
	84.	Leitner et al. "Enhancement of Tumor-Specific Immune Response with Plasmid DNA Replicon Vectors" Cancer Research 60:51-55 (2000)	
	85.	Liljestrom et al. " In Vitro Mutagenesis of a Full-Length cDNA Clone of Semliki Forest Virus: the Small 6,000-Molecular-Weight Membrane Protein Modulates Virus Release" Journal of Virology 65:4107-4113 (1991)	
	86.	Lu et al. "Transmission of Replication-Defective Sindbis Helper Vectors Encoding Capsid and Envelope Proteins" Journal of Virological Methods 91(1):59-65 (2001)	
	87.	Lundstrom "Alphavirus Vectors: Applications for DNA Vaccine Production and Gene Expression" Intervirology 43:247-257 (2000)	
	88.	Maecker et al. "Use of Overlapping Peptide Mixtures as Antigens for Cytokine Flow Cytometry" Journal of Immunological Methods 255:27-40 (2001)	
	89.	McCue and Anders "Soluble Expression and Complex Formation of Proteins Required for HCMV DNA Replication Using the SFV Expression System" Protein Expression and Purification 13:301-312 (1998)	
	90.	Morello et al. "Suppression of Murine Cytomegalovirus (MCMV) Replication with a DNA Vaccine Encoding MCMV M84 (a Homolog of Human Cytomegalovirus pp65)" Journal of Virology 74(8):3696-3708 (2000)	
	91.	Olmsted et al. "Alphavirus Vectors and Virosomes with Modified HIV Genes for Use in Vaccines" U.S. Patent Application Serial No. 10/929,234, filed in the U.S. Patent and Trademark Office on August 30, 2004	
	92.	Olmsted et al. "Characterization of Sindbis Virus Epitopes Important for Penetration in Cell Culture and Pathogenesis in Animals" Virology 148:245-254 (1986)	
	93.	Overwijk et al. "Creating Therapeutic Cancer Vaccines: Notes from the Battlefield" Trends in Immunol. 22(1):5-7 (2001)	
	94.	Pardoll "Cancer Vaccines" Nature Medicine Vaccine Supplement 4(5):525-531 (1998)	
	95.	Pardoll "Spinning Molecular Immunology into Successful Immunotherapy" Nature Reviews –	-
/BB/		Immunology 2:227-238 (2002)	

Examiner Signature	/Benjamin Blumel/	Date Considered	07/16/2007	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute	e form 1449A/P	TO		С	omplete if Known
				Application Number	10/804,331
INFORM	MATION DIS	CLOSUR	E	Filing Date	March 19, 2004
STATEMENT BY APPLICANT		First Named Inventor	Smith		
JIAIL	MENT DIA	I I LIOAN	•	Group Art Unit	1648
(use as m	nany sheets as	necessary)		Examiner Name	Unknown
Sheet	C4	of	C4	Attorney Docket Number	9368.5

/BB/	96.	Pedersen et al. "Separation, Isolation, and Immunological Studies of the Structural Proteins of Venezuelan Equine Encephalomyelitis Virus" J. Virology 14(4):740-744 (1974)	
	97.	Plotkin et al. "Multicenter Trial of Towne Strain Attenuated Virus Vaccine in Seronegative Renal Transplant Recipients" Transplantation 58(11):1176-1178 (1994)	
	98.	Polo et al. "Stable Alphavirus Packaging Cell Lines for Sindbis Virus and Semliki Forest Virus-Derived Vectors" Proc. Natl. Acad. Sci. 96:4598-4603 (1999)	
	99.	Ragupathi et al. "The Case for Polyvalent Cancer Vaccines that Induce Antibodies" Expert Rev. Vaccines 1(2):193-206 (2002)	
	100.	Sadanaga et al. "Dendritic Cell Vaccination with MAGE Peptide is a Novel Therapeutic Approach for Gastrointestinal Carcinomas" Clin Cancer Research 7:2277-2284 (2001)	
	101.	Schlesinger and Dubensky Jr. "Alphavirus Vectors for Gene Expression and Vaccines" Current Opinion in Biotechnology 10(5):434-439 (1999)	
	102.	Slepushkin et al. "Large Scale Purification of a Lentiviral Vector by Size Exclusion Chromatography or Mustang Q ton Exchange Capsule" Bioprocessing Journal pp 89-94 (SeptOct. 2003)	
	103.	Technical Bulletin NO. 166: RiboMAX Large Scale RNA Production Systems – SP6 and T7; Promega Corporation p. 1-11; Revised 09/01; http://www.promega.com/tbs/tb166.pdf on 11/04/2004	
	104.	Temperton "DNA Vaccines Against Cytomegalovirus: Current Progress" International Journal of Antimicrobial Agents 19:169-172 (2002)	
	105.	Waite et al. "Inhibition of Sindbis Virus Production by Media of Low Ionic Strength: Intracellular Events and Requirements for Reversal" Journal of Virology 5:60-71 (1970)	
	106.	Walter et al. "Reconstitution of Cellular Immunity Against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor" The New England Journal of Medicine 333(16):1038-1044 (1995)	
	107.	Ward et al. "Immunotherapeutic Potential of Whole Tumor Cells" Cancer Immunol. Immunother. 51:351-357 (2002)	
	108.	Williamson et al. "Designing HIV-1 Subtype C Vaccines for South Africa" South African Journal of Science 96:318-324 (2000)	
	109.	Wilson et al. "Vaccine Potential of Ebola Virus VP24, VP30, VP35 and VP40 Proteins" Virology 286:384-390 (2001)	
	110.	Yamanaka et al. "Enhancement of Antitumor Immune Response in Glioma Models in Mice by Genetically Modified Dendritic Cells Pulsed with Semliki Forest Virus-Mediated Complementary DNA" J. Neurosurgery 94:474-481 (2001)	
	111.	Yamanaka et al. "Marked Enhancement of Antitumor Immune Responses in Mouse Brain Tumor Models by Genetically Modified Dendritic Cells Producing Semliki Forest Virus-Mediated Interleukin-12" J. Neurosurgery 97:611-618 (2002)	,
/BB/	112.	Ying et al. "Cancer Therapy Using a Self-Replicating RNA Vaccine" Nature Medicine 5(7):823-827 (1999)	

Examiner Signature	/Benjamin Blumei/	Date Considered	07/16/2007

FORM PTO		epartment of Commo		Attorney Docket Number 9368.5			Serial No. 10/804,331			
LIST	OF DOCUME	NTS CITED BY AF	PPLICANT							
OIP	(Use sever	al sheets if necessary	')					<u></u>		
	80151				Applicants:	Smith et al.				
SEP 27	2004 :: 				Filing Date:	March 19, 2	004	Group		
A TRADES	MARKO							1648		
			U. S. PATENT I	OCUME	NTS	r				
Examiner Initial		Document Number	Date		Name ·	Class	Subclass	Filing Date if Appropriate		
								_		
			FOREIGN PATE	NT DOC	JMENTS					
/BB/		Document Number	Date		Country	Class	Subclass	Translation Yes No		
	1.	WO 92/10578	6/25/92		WIPO					
	2.	WO 95/07994	3/23/95		WIPO					
	3.	WO 95/27044	10/12/95		WIPO					
	4.	WO 95/31565	11/23/95		WIPO					
	5.	WO 96/17072	06/06/96		WIPO	<u> </u>				
	6.	WO 96/37220	11/28/96		WIPO		_			
	7.	WO 96/37616	11/28/96		WIPO					
	8.	WO 00/39318	07/06/00		WIPO					
	9.	WO 00/61772	10/19/00		WIPO					
/BB/	10.	WO 02/20721	03/14/02		WIPO					
		OTHER DOCU	MENTS (Includia	ng Author,	Title, Date, Per	tinent Pages,	Etc.)			
/BB/	11	Barouch et al. "ADNA Vaccines b	Augmentation of I by IL-2/Ig Plasmid	mmune Re I Administ	sponses to HIV- ration in Rhesus	1 and Simia Monkeys" <i>I</i>	n Immunodef PNAS 97(8): 4	iciency Virus 1192-4197		
	12		Semliki Forest Vi rticles" <i>Bio/Techr</i>			oduction of	Conditionally	Infectious		
	13		s-Clade Human I V-Infected Zambi					-Lymphocyte		
/BB/	14				Responses in HIV-Infected Zambians" J. Virol. 71(11):8908-8911 (1997) 14. Bredenbeek et al. "Sindbis Virus Expression Vectors: Packaging of RNA Replicons by Using Defective Helper RNAs" Journal of Virology 67:6439-6446 (1993)					

/Benjamin Blumel/

DATE CONSIDERED 07/16/2007

/BB/	15.	Caley et al. "Humoral, Mucosal, and Cellular Immunity in Response to a Human Immunodeficiency Virus Type 1 Immunogen Expressed by a Venezuelan Equine Encephalitis Virus Vaccine Vector" J. Virol. 71(4):3031-3038 (1997)
	16.	Caley et al. "Venezuelan Equine Encephalitis Virus Vectors Expressing HIV-1 Proteins: Vector Design Strategies for Improved Vaccine Efficacy" <i>Vaccine</i> 17:3124-3135 (1999)
	17.	Chappell et al. "A 9-nt Segment of a Cellular mRNA can Function as an Internal Ribosome Site (IRES) and when Present in Linked Multiple Copies Greatly Enhances IRES Activity" <i>PNAS</i> 97(4): 1536-1541 (2000)
	18.	Corsini et al. "Efficiency of Transduction by Recombinant Sindbis Replicon Virus Varies Among Cell Lines, Including Mosquito Cells and Rat Sensory Neurons" <i>BioTechniques</i> 21(3):492-497 (1996)
	19.	Cutler et al. "Mutants of the Membrane-binding Region of Semliki Forest Virus E2 Protein. I. Cell Surface Transport and Fusogenic Activity" <i>The Journal of Cell Biology</i> 102: 889-901 (1986)
	20.	Davis et al. "A Genetically Engineered Live Virus Vaccine for Venezuelan Equine Encephalitis" J. Cell Biochemistry Supplement O No. 17 Part D, Abstract N404 (1993) (Abstract)
	21.	Davis et al. "A molecular genetic approach to the study of Venezuelan equine encephalitis virus pathogenesis" Archives of Virology 9:99-109 (1994)
	22.	Davis et al. "A Viral Vaccine Vector that Expresses Foreign Genes in Lymph Nodes and Protects against Mucosal Challenge" <i>Journal of Virology</i> 70: 3781-3787 (1996)
	23.	Davis et al. "Attenuated Mutants of Venezuelan Equine Encephalitis Virus Containing Lethal Mutations in the PE2 Cleavage Signal Combined with a Second-Site Suppressor Mutation in E1" Virology 212:102-110 (1995)
	24.	Davis et al. "Attenuating Mutations in the E2 Glycoprotein Gene of Venezuelan Equine Encephalitis Virus: Construction of Single and Multiple Mutants in a Full-Length cDNA Clone" <i>Virology</i> 183:20-31 (1991)
	25.	Davis et al. "Immunization against Influenza with Attenuated Venezuelan Equine Encephalitis Virus Vectors" Options for the Control of Influenza III. L. E. Brown and A. W. Hampson, eds. Elsevier, Amsterdam:803-809 (1996)
13B1	26.	Davis et al. "In Vitro Synthesis of Infectious Venezuelan Equine Encephalitis Virus RNA from a cDNA Clone: Analysis of a Viable Deletion Mutant and Mutations Affecting Virulence" Vaccines 90:109-113 (1990)
)	27.	Davis et al. "In Vitro Synthesis of Infectious Venezuelan Equine Encephalitis Virus RNA from a cDNA Clone: Analysis of a Viable Deletion Mutant" Virology 171:189-204 (1989)
BB	28.	Davis et al. "Vaccination of Macaques against Pathogenic Simian Immunodeficiency Virus with Venezuelan Equine Encephalitis Virus Replicon Particles" J. Virol. 74(1):371-378 (2001)
	29.	Dubensky et al. "Sindbis Virus DNA-Based Expression Vectors: Utility for in vitro and in vivo Gene Transfer" Journal of Virology 70:508-519 (1996)
	30.	Dubuisson et al. "Sindbis Virus Attachment: Isolation and Characterization of Mutants with Impaired Binding to Vertebrate Cells" <i>Journal of Virology</i> 67: 3363-3374 (1993)
V.	31.	Favre et al. "Semliki Forest Virus Capsid Protein Expressed by a Baculovirus Recombinant" Archives of Virology 132:307-319 (1993)
/BB/	32.	Feyzi et al. "Structural Requirement of Heparan Sulfate for Interaction with Herpes Simplex Virus Type 1 Virions and Isolated Glycoprotein C" <i>The Journal of Biological Chemistry</i> 272(40):24850-24857 (1997)

/Benjamin Blumel/

DATE CONSIDERED 07/16/2007

/BB/	33.	Frolov et al. "Alphavirus-Based Expression Vectors: Strategies and Applications" <i>Proc. Natl. Acad. Sci. USA</i> 93:11371-11377 (1996)
	34.	Garoff et al. "Expression of Semliki Forest Virus Proteins from Cloned Complementary DNA. 11. The Membrane-spanning Glycoprotein E2 is Transported to the Cell Surface without its Normal Cytoplasmic Domain" <i>The Journal of Cell Biology</i> 97: 652-658 (1983)
	35.	Geigenmuller-Gnirke et al. "Complementation Between Sindbis Viral RNAs Produces Infectious Particles with a Bipartite Genome" <i>Proceedings of the National Academy of Sciences</i> 88:3253-3257 (1991)
	36.	Gingras et al. "Activation of the Translational Suppressor 4E-BP1 Following Infection with Encephalomyocarditis Virus and Poliovirus" <i>Proc. Natl. Acad. Sci. USA</i> 93:5578-5583 (1996)
	37.	Gradi et al. "Proteolysis of Human Eukaryotic Translation Initiation Factor elF4GII, but Not elF4GI, Coincides with the Shutoff of Host Protein Synthesis after Poliovirus Infection" <i>Proc. Natl. Acad. Sc. USA</i> 95:11089-11094 (1998)
	38.	Grieder et al. "Specific Restrictions in the Progression of Venezuelan Equine Encephalitis Virus-Induced Disease Resulting from Single Amino Acid Changes in the Glycoproteins" <i>Virology</i> 206:994-1006 (1995)
	39.	Heidner et al. "Lethality of PE2 Incorporation into Sindbis Virus can be Suppressed by Second-Site Mutations in E3 and E2" <i>Journal of Virology</i> 68: 2683-2692 (1994)
	40.	Heise et al. "An Attenuating Mutation in nsP1 of the Sindbis-Group Virus S.A.AR86 Accelerates Nonstructural Protein Processing and Up-Regulates Viral 26S RNA Synthesis" <i>Journal of Virology</i> 77(2):1149-1156 (2003)
	41.	Herweijer et al. "Self-Amplifying Vectors for Gene Delivery" Advanced Drug Delivery Reviews 27: 16 (1997)
	42.	Hevey et al. "Marburg Virus Vaccines: Comparing Classical and New Approaches" <i>Vaccine</i> 20:586-593 (2002)
	43.	Hirsch et al. "Patterns of Viral Replication Correlate with Outcome in Simian Immunodeficiency Virus (SIV)-Infected Macaques: Effect of Prior Immunization with a Trivalent SIV Vaccine in Modified Vaccinia Virus Ankara" J. Virol. 70(6):3741-3752 (1996)
	44.	Hodgson et al. "Expression of Venezuelan Equine Encephalitis Virus Proteins by Recombinant Baculoviruses" <i>The American Journal of Tropical Medicine and Hygiene</i> . 49:195-196 (1993) (Supplement)
	45.	Holcik and Korneluk "Functional Characterization of the X-Linked Inhibitor of Apoptosis (XIAP) Internal Ribosome Entry Site Element: Role of La Autoantigen in XIAP Translation" <i>Molecular and Cellular Biology</i> 20(13): 4648-4657 (2000)
	46.	Holcik et al. "A New Internal-Ribosome-Entry-Site Motif Potentiates XIAP-Mediated Cytoprotection" Nature Cell Biology 1:190-192 (1999)
	47.	Holcik et al. "The Internal Ribosome Entry Site-Mediated Translation of Antiapoptotic Protein XIA is Modulated by the Heterogeneous Nuclear Ribonucleoproteins C1 and C2" Molecular and Cellula Biology 23(1):280-288 (2003)
	48.	International Search Report of International Application Serial No. PCT/US02/28610 filed Septemb 6, 2002
,	49.	Jalanko "Expression of Semliki Forest Virus Capsid Protein from SV40 Recombinant Virus" FEBS Letters 186:59-64 (1985)
	50.	Jang and Wimmer "Cap-Independent Translation of Encephalomyocarditis Virus RNA: Structural Elements of the Internal Ribosomal Entry Site and Involvement of a Cellular 57-kD RNA-Binding Protein" Genes & Development 4:1560-1572 (1990)
/BB/	51.	Joachims et al. "Cleavage of Poly(A)-Binding Protein by Enterovirus Proteases Concurrent with Inhibition of Translation In Vitro" Journal of Virology 73(1):718-727 (1999)

/Benjamin Blumel/

DATE CONSIDERED 07/16/2007

/BB/	52.	Johnston and Peters "Alphaviruses" <i>Fields Virology</i> , 3 rd ed., Lippincott-Raven Publishers, Philadelphia, Chapt, 28:843-898 (1996)
	53.	Johnston and Smith "Selection for Accelerated Penetration in Cell Culture Coselects for Attenuated Mutants of Venezuelan Equine Encephalitis Virus" Virology 162:437-443 (1988)
	54.	Kinney et al. "Attenuation of Venezuelan Equine Encephalitis Virus Strain TC-83 Is Encoded by the 5'-Noncoding Region and the E2 Envelope Glycoprotein" <i>Journal of Virology</i> 67:1269-1277 (1993)
	55.	Kinney et al. "The Full-Length Nucleotide Sequences of the Virulent Trinidad Donkey Strain of Venezuelan Equine Encephalitis Virus and its Attenuated Vaccine Derivative, Strain TC-83" Virology 170:19-30 (1989)
	56.	Klimstra et al. "Adaptation of Sindbis Virus to BHK Cells Selects for Use of Heparan Sulfate as an Attachment Receptor" <i>Journal of Virology</i> 72(9):7357-7366 (1998)
	57.	Kondor-Koch et al. "Expression of Semliki Forest Virus Proteins from Cloned Complementary DNA. I. The Fusion Activity of the Spike Glycoprotein" J. Cell Biology 97(3):644-651 (1983)
	58.	Lee et al. "Efficient Long-Term Coexpression of a Hammerhead Ribozyme Targeted to the U5 Region of HIV-1 LTR by Linkage to the Multidrug-Resistance Gene" Antisense & Nucleic Acid Drug Development 7:511-522 (1997)
	59.	Lemm et al. "Polypeptide Requirements for Assembly of Functional Sindbis Virus Replication Complexes: a Model for the Temporal Regulation of Minus- and Plus-Strand RNA Synthesis" <i>The EMBO Journal</i> 13:2925-2934 (1994)
	60.	Leone et al. "In Vitro Synthesis of the Gene Coding for the Glycoprotein E1 of Sindbis Virus" Microbiologica 8(2):123-130 (1985) (Abstract)
	61.	Li et al. "Production of Infectious Recombinant Moloney Murine Leukemia Virus Particles in BHK Cells Using Semliki Forest Virus-Derived RNA Expression Vectors" <i>Proc. Natl. Acad. Sci. USA</i> 93: 11658-11663 (October 1996)
	62.	Liljeström "Alphavirus Expression Systems" Current Opinion in Biotechnology 5:495-500 (1994)
	63.	Liljestrom et al. "A New Generation of Animal Cell Expression Vectors Based on the Semliki Forest Virus Replicon" <i>Bio/Technology</i> 9:1356-1361 (1991)
	64.	Lobigs et al. "Fusion Function of the Semliki Forest Virus Spike is Activated by Proteolytic Cleavage of the Envelope Glycoprotein Precursor p62" <i>Journal of Virology</i> 64: 1233-1240 (1990)
	65.	Lundström et al. "Secretion of Semliki Forest Virus Membrane Glycoprotein E1 from Bacillus subtilis" Virus Research 2:69-83 (1985)
	66.	Martinez-Salas et al. "Functional Interactions in Internal Translation Initiation Directed by Viral and Cellular IRES Elements" Journal of General Virology 82:973-984 (2001)
	67.	McKnight et al. "Deduced Consensus Sequence of Sindbis Virus Strain AR339: Mutations Contained in Laboratory Strains Which Affect Cell Culture and <i>In Vivo</i> Phenotypes" <i>Journal of Virology</i> 70(3): 1981-1989 (1996)
	68.	Melancon et al. "Processing of the Semliki Forest Virus Structural Polyprotein: Role of the Capsid Protease" Journal of Virology 61:1301-1309 (1987)
	69.	Melancon et al. "Reinitiation of Translocation in the Semliki Forest Virus Structural Polyprotein: Identification of the Signal for the E1 Glycoprotein" <i>The EMBO Journal</i> 5:1551-1560 (1986)
/BB/	70.	Morgenstern et al. "Advanced Mammalian Gene Transfer: High Titre Retroviral Vectors with Multiple Drug Selection Markers and a Complementary Helper-Free Packaging Cell Line" Nucleic Acids Research 18:3587-3596 (1990)

/Benjamin Blumel/

DATE CONSIDERED 07/16/2007

/BB/	89.	Strauss and Strauss "The Alphaviruses: Gene Expression, Replication, and Evolution" Microbiological Reviews 58:491-562 (1994)
	88.	Strauss and Strauss "Alphavirus Proteinases" Seminars In Virology 1:347-356 (1990)
	87.	Smerdou and Liljestrom "Two-Helper RNA System for Production of Recombinant Semliki Forest Virus Particle" Journal of Virology 73(2):1092-1098 (1999)
	86.	Sjöberg et al. "A Significantly Improved Semliki Forest Virus Expression System Based on Translation Enhancer Segments from the Viral Capsid Gene" <i>Bio/Technology</i> 12:1127-1131 (1994)
	85.	Simpson et al. "Complete Nucleotide Sequence and Full-Length cDNA Clone of S.A.AR86, a South African Alphavirus Related to Sindbis" <i>Virology</i> 222:464-469 (1996)
	84.	Schoepp and Johnston "Directed Mutagenesis of a Sindbis Virus Pathogenesis Site" Virology 193:149-159 (1993)
	83.	Schlesinger and Schlesinger "Togaviridae: The Viruses and Their Replication" Fields Virology, 3 rd edition. (Fields et al., eds.) Lipincott-Raven Publishers, Philadelphia (1996) pp. 825-841
	82.	Schlesinger "Alphaviruses - Vectors for the Expression of Heterologous Genes" <i>TiBTech</i> 11:18-22 (1993)
	81.	Salminen et al. "Membrane Fusion Process of Semliki Forest Virus II: Cleavage-dependent Reorganization of the Spike Protein Complex Controls Virus Entry" <i>The Journal of Cell Biology</i> 116 349-357 (1992)
	80.	Russell et al. "Sindbis Virus Mutations Which Coordinately Affect Glycoprotein Processing, Penetration, and Virulence in Mice" <i>Journal of Virology</i> 63:1619-1629 (1989)
	79.	Roberts and Belsham "Complementation of Defective Picornavirus Internal Ribosome Entry Site (IRES) Elements by the Coexpression of Fragments of the IRES" Virology 227:53-62 (1997)
	78.	Riedel "Different Membrane Anchors Allow the Semliki Forest Virus Spike Subunit E2 to Reach the Cell Surface" Journal of Virology 54:224-228 (1985)
	77.	Rice et al. "Expression of Sindbis Virus Structural Proteins via Recombinant Vaccinia Virus: Synthesis, Processing, and Incorporation into Mature Sindbis Virions" <i>J. Virology</i> 56:227-239 (1985)
	76.	Pushko et al. "Replicon-Helper Systems from Attenuated Venezuelan Equine Encephalitis Virus: Expression of Heterologous Genes in Vitro and Immunization Against Heterologous Pathogens in Vivo" Virology 239:389-401 (1997)
	75.	Presley et al. "Proteolytic Processing of the Sindbis Virus Membrane Protein Precursor PE2 is Nonessential for Growth in Vertebrate Cells but is Required for Efficient Growth in Invertebrate Cells" Journal of Virology 65:1905-1909 (1991)
	74.	Polo and Johnston "Attenuating Mutations in Glycoproteins E1 and E2 of Sindbis Virus Produce a Highly Attenuated Strain When Combined in Vitro" Journal of Virology 64:4438-4444 (1990)
	73.	Paredes et al. "Three-dimensional Structure of a Membrane-Containing Virus" <i>Proc. Natl. Acad. Sci. USA</i> 90:9095-9099 (1993)
	72.	Orkin et al. "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy" (1995)
/BB/	71.	Oker-Blom et al. "Expression of Sindbis Virus 26S cDNA in Spodoptera frugiperda (Sf9) Cells, Using a Baculovirus Expression Vector" J. Virology 63:1256-1264 (1989)

/Benjamin Blumel/

DATE CONSIDERED 07/16/2007

/BB/	90.	Suomalainen et al. "Spike Protein-Nucleocapsid Interactions Drive the Budding of Alphaviruses" Journal of Virology 66(8):4737-4747 (1992)
	91.	Sykes and Johnston "Genetic Live Vaccines Mimic the Antigenicity but Not Pathogenicity of Live Viruses" DNA and Cell Biology 18(7):521-531 (1999)
	92.	Thompson and Sarnow "Enterovirus 71 Contains a Type I IRES Element that Functions When Eukaryotic Initiation Factor eIF4G is Cleaved" <i>Virology</i> 315:259-266 (2003)
	93.	Ubol et al. "Neurovirulent Strains of Alphavirus Induce Apoptosis in bcl-2-Expresing Cells: Role of a Single Amino Acid Change in the E2 Glycoprotein" <i>Proc. National Academy Sciences</i> 91: 5202-5206 (1994)
	94.	Van der Velden et al. "Defective Point Mutants of the Encephalomyocarditis Virus Internal Ribosome Entry Site can be Complemented in Trans" Virology 214:82-90 (1995)
	95.	Verma et al. "Gene Therapy - Promises, Problems and Prospects" Nature 389:239-242 (1997)
	96.	Weiss and Schlesinger "Recombination between Sindbis Virus RNAs" Journal of Virology 65: 4017-4025 (1991)
	97.	Wen et al. "Expression of Genes Encoding Vesicular Stomatitis and Sindbis Virus Glycoproteins in Yeast Leads to Formation of Disulfide-Linked Oligomers" Virology 153:150-154 (1986)
	98.	Williamson et al. "Characterization and Selection of HIV-1 Subtype C Isolates for Use in Vaccine Development" AIDS Research and Human Retroviruses 19(2):133-144 (2003)
	99.	Xiong et al. "Sindbis Virus: An Efficient, Broad Host Range Vector for Gene Expression in Animal Cells" Science 243:1188-1191 (1989)
	100.	Yang and Sarnow "Location of the Internal Ribosome Entry Site in the 5' Non-Coding Region of the Immunoglobulin Heavy-Chain Binding Protein (BiP) mRNA: Evidence for Specific RNA-Protein Interactions" <i>Nucleic Acids Research</i> 25(14):2800-2807 (1997)
/BB/	101.	Zhao et al. "Role of Cell Surface Spikes in Alphavirus Budding" Journal of Virology 66:7089-7095 (1992)